• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by AbCellera Biologics Inc.

    11/14/24 4:11:49 PM ET
    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $ABCL alert in real time by email
    SC 13G/A 1 tm2426483d1_sc13ga.htm SC 13G/A

     

     

     

    SCHEDULE 13G

     

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    AbCellera Biologics Inc.

    (Name of Issuer)

     

    Common Shares, no par value per share 

    (Title of Class of Securities)

     

    00288U106

     

    (CUSIP Number)

     

    September 30, 2024

     
      (Date of Event which Requires Filing of this Statement)  

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

       x Rule 13d-1(b)
         
       ¨ Rule 13d-1(c)
         
       ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 00288U106

     

    1

    NAMES OF REPORTING PERSONS

     

    Baker Bros. Advisors LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨
    (b) 
    ¨
    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5

    SOLE VOTING POWER

     

    27,525,640

    6

    SHARED VOTING POWER

     

    -0-

    7

    SOLE DISPOSITIVE POWER

     

    27,525,640

    8

    SHARED DISPOSITIVE POWER

     

    -0-

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    27,525,640

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (See Instructions)
    ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.3% (1)

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    IA, PN

     

      (1) Based upon 294,665,532 common shares (“Common Shares”) of AbCellera Biologics Inc. (the “Issuer”) outstanding as of August 1, 2024, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on August 6, 2024.

     

    Page 1 of 9 Pages

     

     

    CUSIP No. 00288U106

     

    1

    NAMES OF REPORTING PERSONS

     

    Baker Bros. Advisors (GP) LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨
    (b) 
    ¨
    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    5

    SOLE VOTING POWER

     

    27,525,640

    6

    SHARED VOTING POWER

     

    -0-

    7

    SOLE DISPOSITIVE POWER

     

    27,525,640

    8

    SHARED DISPOSITIVE POWER

     

    -0-

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    27,525,640

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (See Instructions)
    ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.3% (1)

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    HC, OO

     

      (1) Based upon 294,665,532 Common Shares outstanding as of August 1, 2024, as reported in the Issuer’s Form 10-Q filed with the SEC on August 6, 2024.

     

    Page 2 of 9 Pages

     

     

    CUSIP No. 00288U106

     

    1

    NAMES OF REPORTING PERSONS

     

    Felix J. Baker

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨
    (b) 
    ¨
    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    5

    SOLE VOTING POWER

     

    27,525,640

    6

    SHARED VOTING POWER

     

    -0-

    7

    SOLE DISPOSITIVE POWER

     

    27,525,640

    8

    SHARED DISPOSITIVE POWER

     

    -0-

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    27,525,640

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (See Instructions)
    ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.3% (1)

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN, HC

     

      (1) Based upon 294,665,532 Common Shares outstanding as of August 1, 2024, as reported in the Issuer’s Form 10-Q filed with the SEC on August 6, 2024.

     

    Page 3 of 9 Pages

     

     

    CUSIP No. 00288U106

     

    1

    NAMES OF REPORTING PERSONS

     

    Julian C. Baker

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨
    (b) 
    ¨
    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

    5

    SOLE VOTING POWER

     

    27,525,640

    6

    SHARED VOTING POWER

     

    -0-

    7

    SOLE DISPOSITIVE POWER

     

    27,525,640

    8

    SHARED DISPOSITIVE POWER

     

    -0-

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    27,525,640

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (See Instructions)
    ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.3% (1)

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN, HC

     

      (1) Based upon 294,665,532 Common Shares outstanding as of August 1, 2024, as reported in the Issuer’s Form 10-Q filed with the SEC on August 6, 2024.

     

    Page 4 of 9 Pages

     

     

    Amendment No. 1 to Schedule 13G

     

    This Amendment No. 1 to Schedule 13G amends the previously filed Schedule 13G filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP) LLC (the “Adviser GP”), Julian C. Baker and Felix J. Baker (collectively, the “Reporting Persons”). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.

     

    Item 1(a) Name of Issuer:

     

    AbCellera Biologics Inc. (the “Issuer”)

     

    Item 1(b) Address of Issuer’s Principal Executive Offices:

     

    2215 Yukon Street

     

    Vancouver, BC V5Y 0A1

     

    Item 2(a) Name of Person Filing:

     

    This Amendment No. 1 is being filed jointly by the Reporting Persons.

     

    Item 2(b) Address of Principal Business Office or, if None, Residence:

     

    The business address of each of the Reporting Persons is:

     

    c/o Baker Bros. Advisors LP

     

    860 Washington Street, 3rd Floor

     

    New York, NY 10014

     

    (212) 339-5690

     

    Item 2(c) Citizenship:

     

    The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

     

    Item 2(d) Title of Class of Securities:

     

    Common Shares, no par value per share  (“Common Shares”)

     

    Item 2(e) CUSIP Number:

     

    00288U106

     

    Page 5 of 9 Pages

     

     

    Item 3 If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a:

     

      (a)¨  Broker or dealer registered under Section 15 of the Exchange Act.
          
      (b)¨ Bank as defined in section 3(a)(6) of the Exchange Act.
          
      (c)¨ Insurance company as defined in section 3(a)(19) of the Exchange Act.
          
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940.
          
      (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
          
      (f) ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
          
      (g)x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
          
      (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
          
      (i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940.
          
      (j)¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

     

    Item 4 Ownership:

     

    Items 5 through 9 and 11 of each of the cover pages to this Amendment No. 1 are incorporated herein reference. Set forth below is the aggregate number of Common Shares directly held by each of Baker Brothers Life Sciences, L.P. (“Life Sciences”) and 667, L.P. (“667”, and together with Life Sciences, the “Funds”). The information set forth below is based on 294,665,532 Common Shares outstanding as of August 1, 2024 as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 6, 2024. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended.

     

    Page 6 of 9 Pages

     

     

    Name   Number of Common
    Shares we own or have
    the right to acquire within
    60 days
        Percent of
    Class
    Outstanding
     
    667, L.P.     2,156,480       0.7 %
    Baker Brothers Life Sciences, L.P.     25,369,160       8.6 %
    Total     27,525,640       9.3 %

     

    Pursuant to the management agreements, as amended, among the Adviser, the Funds and their respective general partners, the Funds’ respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds, and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds’ investments and voting power over investments.

     

    The Adviser GP is the sole general partner of the Adviser. The Adviser GP, Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds.

     

    Item 5 Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨. N/A

     

    Item 6 Ownership of More than Five Percent on Behalf of Another Person:

     

    N/A

     

    Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    The information in Item 4 is incorporated herein by reference.

     

    Page 7 of 9 Pages

     

     

    Item 8 Identification and Classification of Members of the Group:

     

    N/A

     

    Item 9 Notice of Dissolution of Group:

     

    N/A

     

    Item 10 Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    November 14, 2024

     

      BAKER BROS. ADVISORS LP
       
      By: Baker Bros. Advisors (GP) LLC, its general partner
         
      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
        Title: President
         
      BAKER BROS. ADVISORS (GP) LLC
         
      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
        Title: President
         
        /s/ Julian C. Baker
        Julian C. Baker
         
        /s/ Felix J. Baker
        Felix J. Baker

     

    Page 9 of 9 Pages

     

    Get the next $ABCL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABCL

    DatePrice TargetRatingAnalyst
    8/20/2024Buy → Hold
    The Benchmark Company
    2/22/2024$9.00Hold → Buy
    The Benchmark Company
    12/5/2023$6.00Overweight
    KeyBanc Capital Markets
    11/6/2023Buy → Hold
    The Benchmark Company
    10/13/2023$20.00Overweight
    Piper Sandler
    2/28/2023Outperform
    Cowen
    12/15/2022$30.00Buy
    Goldman
    11/16/2022$29.00Buy
    Truist
    More analyst ratings

    $ABCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by AbCellera Biologics Inc.

      SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)

      11/14/24 4:11:49 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13G filed by AbCellera Biologics Inc.

      SC 13G - AbCellera Biologics Inc. (0001703057) (Subject)

      2/14/24 4:21:54 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13G/A filed by AbCellera Biologics Inc. (Amendment)

      SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)

      2/13/24 5:01:32 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care

    $ABCL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

      ABCL575 is an Fc-silenced, half-life extended investigational antibody medicine that is being developed for the treatment of atopic dermatitis AbCellera anticipates starting the Phase 1 clinical trial for ABCL575 in Q3 2025 AbCellera (NASDAQ:ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL575, an investigational antibody antagonist targeting OX40 ligand (OX40L) that is being developed for the treatment of moderate-to-severe atopic dermatitis (AD), with potential applications to other inflammatory and autoimmune conditions. The Phase 1 study is anticipated to begin in Q3 of 2025 and will evalu

      5/30/25 1:00:00 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

      AbCellera anticipates starting the Phase 1 clinical trial for ABCL635 in Q3 2025 AbCellera (NASDAQ:ABCL) today announced it has received a No Objection Letter (NOL) from Health Canada authorizing its Clinical Trial Application (CTA) for ABCL635, an investigational antibody antagonist targeting neurokinin 3 receptor (NK3R) that is being developed for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. "Vasomotor symptoms of menopause affect millions of women, with significant impacts on their well-being, and their personal and professional lives," said Natalya Nazarenko, MD, Executive Medical Director at AbCel

      5/14/25 5:00:00 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

      The Federal Circuit rejects Bruker Cellular's invalidity challenge to AbCellera's patent for microfluidic devices and their use in culturing cells AbCellera (NASDAQ:ABCL) today announced that the United States Court of Appeals for the Federal Circuit (CAFC) has by a Rule 36 Order affirmed judgment of validity of its U.S. Patent No. 10,087,408 ("the ‘408 Patent"). AbCellera's ‘408 Patent is directed to microfluidic devices and using such devices to culture and selectively recover cells. Previously Berkeley Lights Inc., now Bruker Cellular Analysis, Inc. (Bruker), a subsidiary of Bruker Corporation, challenged the claims of the ‘408 Patent alleging invalidity based on anticipation and obvio

      5/12/25 3:30:00 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care

    $ABCL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Thermopylae Holdings Ltd. bought $742,243 worth of shares (343,631 units at $2.16), increasing direct ownership by 0.62% to 56,143,640 units (SEC Form 4)

      4 - AbCellera Biologics Inc. (0001703057) (Issuer)

      3/11/25 6:42:57 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • Director Montalbano John S. bought $57,500 worth of shares (25,000 units at $2.30), increasing direct ownership by 17% to 171,000 units (SEC Form 4)

      4 - AbCellera Biologics Inc. (0001703057) (Issuer)

      3/10/25 5:11:03 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • Director Montalbano John S. bought $140,568 worth of shares (60,000 units at $2.34), increasing direct ownership by 70% to 146,000 units (SEC Form 4)

      4 - AbCellera Biologics Inc. (0001703057) (Issuer)

      3/7/25 3:32:01 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care

    $ABCL
    SEC Filings

    See more
    • AbCellera Biologics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - AbCellera Biologics Inc. (0001703057) (Filer)

      5/30/25 1:46:41 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • AbCellera Biologics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - AbCellera Biologics Inc. (0001703057) (Filer)

      5/14/25 5:15:04 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • AbCellera Biologics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - AbCellera Biologics Inc. (0001703057) (Filer)

      5/13/25 2:33:02 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care

    $ABCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ABCL
    Financials

    Live finance-specific insights

    See more
    • AbCellera Biologics downgraded by The Benchmark Company

      The Benchmark Company downgraded AbCellera Biologics from Buy to Hold

      8/20/24 6:47:45 AM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • AbCellera Biologics upgraded by The Benchmark Company with a new price target

      The Benchmark Company upgraded AbCellera Biologics from Hold to Buy and set a new price target of $9.00

      2/22/24 6:35:00 AM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • KeyBanc Capital Markets initiated coverage on AbCellera Biologics with a new price target

      KeyBanc Capital Markets initiated coverage of AbCellera Biologics with a rating of Overweight and set a new price target of $6.00

      12/5/23 7:12:21 AM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • AbCellera Reports Q1 2025 Business Results

      AbCellera (NASDAQ:ABCL) today announced financial results for the first quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "After completion of a successful first quarter, we are excited to introduce ABCL635 as a potential first-in-class antibody for the non-hormonal treatment of vasomotor symptoms (hot flashes) associated with menopause. ABCL635 is positioned as a next-generation neurokinin 3 receptor (NK3R) antagonist with an improved safety profile and convenient dosing regimen. If successful, we believe it has the potential to be a highly differentiated product in a large and established market," said Carl Hansen, P

      5/8/25 4:05:00 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

      AbCellera (NASDAQ:ABCL) will announce its first quarter 2025 financial results on Thursday, May 8, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data

      4/3/25 4:05:00 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • AbCellera Reports Full Year 2024 Business Results

      AbCellera (NASDAQ:ABCL) today announced financial results for the full year 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "In 2024 we made significant progress in transitioning from a platform company to a clinical-stage biotech, including advancing our internal pipeline and completing significant investments in our capabilities. We also maintained our strong cash position, closing the year with over $800 million in available liquidity to execute on our strategy," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "As a result, we enter 2025 on track to initiate Phase 1 clinical trials for our first two programs, ABCL635

      2/27/25 4:05:00 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care

    $ABCL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Thermopylae Holdings Ltd. bought $742,243 worth of shares (343,631 units at $2.16), increasing direct ownership by 0.62% to 56,143,640 units (SEC Form 4)

      4 - AbCellera Biologics Inc. (0001703057) (Issuer)

      3/11/25 6:42:57 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • Director Montalbano John S. bought $57,500 worth of shares (25,000 units at $2.30), increasing direct ownership by 17% to 171,000 units (SEC Form 4)

      4 - AbCellera Biologics Inc. (0001703057) (Issuer)

      3/10/25 5:11:03 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • Director Montalbano John S. bought $140,568 worth of shares (60,000 units at $2.34), increasing direct ownership by 70% to 146,000 units (SEC Form 4)

      4 - AbCellera Biologics Inc. (0001703057) (Issuer)

      3/7/25 3:32:01 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care

    $ABCL
    Leadership Updates

    Live Leadership Updates

    See more
    • AbCellera Announces Resignation of Board Member

      AbCellera (NASDAQ:ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective March 7, 2024. "AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field," said Peter Thiel. "I am proud to have helped them with their mission." Mr. Thiel joined AbCellera's Board of Directors in November 2020 and served as the Chairman of the Company's Nominating and Corporate Governance Committee. Effective March 7, 2024, Dr. Andrew Lo, a member of the Company's Board of Directors, will be appointed to the Nominating and Corporate Governance Committee of the Board of Dir

      2/23/24 4:30:00 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer

      TORONTO, June 13, 2023 /PRNewswire/ -- DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain disorders and aging, today announced the appointment of John Reilly as the company's Chief Executive Officer and member of the Board of Directors. Mr. Reilly brings two decades of leadership experience building and creating value for biotechnology companies, with deep knowledge and expertise in corporate strategy, business dev

      6/13/23 7:59:57 AM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • AbCellera Announces Changes to Its Board of Directors

      AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced changes to its Board of Directors with the appointment of Andrew W. Lo, Ph.D., as an independent director and the resignation of John Hamer, Ph.D. Changes are effective immediately. Dr. Lo has developed new financial engineering tools and business models for drug and device development and healthcare delivery, statistical methods for incorporating patient preferences into the drug approval process, and machine-learning for predicting clinical trial outcomes. He will serve on the Audit and Compensation Committees of the Board of Directors. "Andrew is a d

      12/7/21 9:00:00 AM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care